INTRODUCTION
The amygdala is a subcortical structure that plays a key role in attaching emotional significance to sensory stimuli. Pain is a complex experience that includes the subjective experience of the pain as well as the emotional and cognitive response to it. The central nucleus of the amygdala (CeA), which forms the output nucleus of the amygdaloid complex , receives direct nociceptive inputs from trigeminal and spinal sources via the pontine parabrachial nucleus (PB), an anatomical organization that has been described as the ''nociceptive amygdala'' (Neugebauer et al., 2004) . In turn, the CeA has projections to hypothalamic and brainstem regions that regulate physiological responses as well as extensive projections to cortical areas that initiate affective responses (Davis and Whalen, 2001; LeDoux, 2000; Sah et al., 2003) . The presence of direct nociceptive inputs to the CeA, coupled with its role in emotional processing, makes this region well positioned to integrate nociceptive activity with emotional arousal. Thus, pain states are well known to have significant negative affective value, and chronic pain can ultimately lead to anxiety and depression (Craig, 2006) , both of which are recognized to involve the amygdala (Davis and Whalen, 2001) .
The noradrenergic system arises from cell groups in the brainstem that have projections to the spinal cord (Fields et al., 2006; Yoshimura and Furue, 2006) , as well as ascending projections that target almost the entire forebrain (Bouret and Sara, 2005) . Visceral activation of these cell groups results in major effects on the response to pain (Jones, 1991) . The nociceptive actions of noradrenaline from its actions on afferent activity as it enters the spinal cord are well known (Fields et al., 2006; Yoshimura and Furue, 2006) . However, noradrenaline also has cognitive and behavioral actions due to its supraspinal actions (Berntson et al., 2003; Yaksh, 2006) . While exogenously applied noradrenaline has a range of actions on central neurons (Nicoll et al., 1990) , its actions in modulating particular sensory inputs are not well understood. The CeA receives a particularly dense ascending noradrenergic projection (Fallon et al., 1978; Riche et al., 1990; ZardettoSmith and Gray, 1995) and has a high level of a 2A adrenoceptor expression (Talley et al., 1996) . Given the presence of a strong nociceptive input into the CeA, it is likely that the affective actions of noradrenergic stimulation may result from a supraspinal action on nociceptive inputs to the amygdaloid complex. In agreement with this, monoamine uptake blockers that have been widely used as analgesics (Sindrup et al., 2005) are particularly effective when delivered into the cerebral ventricles, indicating a supraspinal mode of action (Sawynok et al., 2001 ). However, the cellular mechanisms that may underlie these supraspinal actions of noradrenaline are not known.
Recent anatomical data have revealed that fibers projecting from the PB to the lateral division of the central amygdala (CeAL) targeted single neurons in the CeA, terminating in perisomatic basket terminals (Sarhan et al., 2005) . Here we show that these terminals form large excitatory synapses with multiple release sites that are potently inhibited by synaptically released noradrenaline. This inhibition results from presynaptic activation of a2 adrenoceptors that reduces synaptic transmission by blocking some release sites by an action that is mediated by G protein bg subunits and is downstream of calcium influx. These findings show that noradrenergic stimulation modulates transmission of nociceptive information into the amygdala by a presynaptic mechanism.
RESULTS
The parabrachial (PB) nucleus sends a large projection to the central amygdala, with axons terminating in both its capsular (CeAC) and the lateral (CeAL) division (Sarhan et al., 2005) . We first identified the course of these axons in coronal brain slices by injecting the tracer DiI into the PB ( Figure 1A ). DiI injection resulted in extensive labeling of terminals in the CeAL (Figures 1B and 1C) and revealed that projections from PB neurons travel along the ventral amygdaloid fiber tract (VAF, asterisk in Figure 1D ) and course around the dorsal extent of the optic tract before entering the CeA via the stria terminalis. On entering the CeA, individual PB axons form large perisomatic basketlike terminations around the somata of CeAL neurons (Figure 1) (Sarhan et al., 2005) .
Noradrenaline Inhibits Parabrachial Excitatory Input to the Central Amygdala
To examine the properties of PB inputs to CeAL neurons, whole-cell recordings were made from neurons in the CeAL that were targeted by DiI-positive PB terminals (Figures 2A and 2B ). PB afferents were activated using minimal stimulation (Raastad et al., 1992) within the VAF bundle to activate single fiber inputs (Figures 1D and 2A) . At a holding potential of À60 mV, stimulation of PB afferents evoked a large (122.1 ± 14.0 pA, n = 14) excitatory postsynaptic current (EPSC). This response was all or none, and increasing the stimulation strength did not change its amplitude ( Figure 2C ), consistent with activation of perisomatic basket terminals originating from a single axon (Sarhan et al., 2005) . Notably, the evoked EPSC was significantly larger (p < 0.01, n = 6 cells) than miniature asynchronous synaptic events recorded from the same terminals ( Figure 5 ; 13.6 ± 2.6 pA, n = 6), indicating that activation of these single fiber inputs results in transmitter release from multiple release sites. Recording in current clamp using potassium-based internal solutions and minimal stimulation resulted in a large, fast-rising evoked postsynaptic potential (EPSP) ( Figure 2D , average amplitude 9.1 ± 1.5 mV, n = 8 cells) that was sufficient to drive CeAL cells to threshold in most cases (7 out of 8 cells recorded). Both the EPSP and the evoked inward current were completely abolished by the AMPA/kainate receptor antagonist NBQX ( Figure 2E , n = 3), showing that glutamate is the transmitter at these synapses.
To confirm that minimal stimulation in the VAF pathway activated basket synapses in the CeA that originated in the PB, we loaded a low-affinity calcium indicator, magnesium green, into the basket terminal (see Experimental Procedures) to image action potential-driven presynaptic calcium influx in the PB terminals. Terminals loaded with indicator could be clearly seen as baskets in the CeAL, similar to those revealed by injection of DiI into the PB (Figure 1) . Electrical stimulation of the VAF pathway evoked transient rises in calcium in these basket terminals (Figure 2F ). These calcium rises were insensitive to the glutamate receptor antagonists NBQX and d-APV (10 mM and 30 mM, respectively, n = 2) but were blocked by the sodium channel blocker tetrodotoxin (1 mM, n = 2), confirming that the recorded calcium signals were action potential driven.
These results show that single fiber PB afferents to neurons in the CeAL form large synapses that can drive these neurons to threshold. Application of noradrenaline (10 mM) caused rapid and reversible inhibition of the PB input ( Figure 3A ), arresting synaptically induced firing (4/4 cells), and reduced the size of the evoked EPSP by 63.2% ± 4.7% (using subthreshold EPSPs for control, p < 0.01, n = 4). These effects of noradrenaline were reversed by the selective a 2 -adrenoceptor antagonist yohimbine, restoring synaptically evoked firing in 3/3 neurons (20 mM, Figure 3A ), and were not due to modulation of the properties of the postsynaptic neuron, as action potentials evoked by a brief depolarizing current injection were unaffected by noradrenaline ( Figure 3A) .
To further pharmacologically characterize the effects of noradrenaline, we examined its actions on excitatory postsynaptic currents (EPSCs). Stimulating electrodes were placed in the VAF pathway and the basolateral amygdala (BLA input) to activate two independent inputs to CeAL neurons (Lopez de Armentia and Sah, 2004) . Application of noradrenaline (10 mM) resulted in a rapid and reversible inhibition of the PB-EPSC of 70.9% ± 3.7% (n = 21, p < 0.01), with no effect on the BLA-EPSC (Figure 3B; 1.1% ± 10.9%, n = 8, p > 0.44). This effect of noradrenaline was dose dependent, reaching maximal effect at 100 mM, and the dose-response curve was well fitted with a Hill equation with an EC 50 of 2.3 mM ( Figure 3C ). The specific a 2 -adrenoceptor antagonist yohimbine (20 mM) blocked noradrenergic inhibition of the PB input ( Figures 3D and 3E : 8.9% ± 3.0% p > 0.05, n = 7), whereas the selective a 1 -adrenoceptor antagonist prazosin had no effect ( Figure 3E : 58.8% ± 8.3% inhibition, p < 0.05, n = 5). Furthermore, the a 2 -subtype-selective adrenoceptor agonist clonidine (20 mM) both inhibited the PB input (75.8% ± 2.8%, n = 5, p < 0.05) and occluded the effect of subsequently applied noradrenaline (9.5% ± 10.0% inhibition, n = 4, p = 0.42, data not shown). a 1 -and b-adrenoceptor-selective agonists (cirazoline and isoprenaline) had no significant effect on the PB input (4.1% ± 1.2% facilitation and 10.2% ± 14.1% inhibition, respectively, n = 4 for each, data not shown). Thus, noradrenaline effectively reduces synaptic transmission at parabrachial inputs to CeAL neurons by activating a2 adrenoceptors.
Noradrenaline Acts Presynaptically at PB-CeAL Synapses Noradrenergic block of the PB-evoked EPSC could either be due to a change in transmitter release or due to modulation of postsynaptic receptors. To determine whether noradrenaline modulates the postsynaptic AMPA receptor pool, we examined spontaneous excitatory postsynaptic currents (sEPSC, isolated in 100 mM picrotoxin) recorded in voltage clamp at a holding potential of À60 mV. Neither the amplitude nor the frequency of sEPSCs ( Figure 4A ) was significantly changed from control by noradrenaline (4.4% ± 3.4% decrease and 5.7% ± 8.2% decrease, respectively, p > 0.05, n = 16). Miniature EPSCs recorded in the presence of tetrodotoxin (data not shown) showed similar insensitivity to noradrenaline (7.7% ± 6.9% decrease in amplitude and 3.6% ± 6.4% increase in frequency, p > 0.05 for both, n = 6). These results suggest that the postsynaptic AMPA receptors are not altered by noradrenaline. However, CeAL neurons receive inputs from a variety of different sources, some of which are insensitive to noradrenaline (e.g., Figure 3B ). Thus, it is conceivable that the majority of the spontaneous events we have measured are from inputs that are not affected by noradrenaline. To isolate unitary synaptic responses arising from PB inputs, we recorded asynchronous evoked release events by replacing extracellular calcium with 5 mM strontium (Goda and Stevens, 1994) and activated single PB afferents as before ( Figure 4B ). The amplitude of these events (occurring between 20 ms and 120 ms poststimulus to exclude synchronously released evoked events) was not changed by addition of 10 mM noradrenaline (7.3% ± 12.3%, Figures 4B and 4C ), indicating that noradrenergic stimulation does not modulate postsynaptic AMPA receptors. However, the frequency of strontiumevoked asynchronous events occurring in this delayed time window was reduced by noradrenaline (43.1% ± 4.5%, n = 6, p < 0.01), suggesting a presynaptic locus for the effect of noradrenaline at this synapse. (E) Summary data showing the percent inhibition of 10 mM noradrenaline on BLA inputs (unfilled column) and on PB inputs in control, 20 mM yohimbine, and 10 mM prazosin (filled columns left to right, respectively, p < 0.01, n = 8, 21, 7, and 5, respectively). GABA receptors have been blocked with 100 mM picrotoxin and 3 mM CGP55845A. Error bars show ± SEM.
Glutamatergic synapses on CeAL neurons are typical dual-component synapses that express both AMPA and NMDA receptors . If the adrenergic inhibition is mediated by a presynaptic mechanism, then evoked EPSCs mediated by NMDA receptors should be similarly inhibited by noradrenaline. We therefore recorded evoked NMDA receptor-mediated EPSCs at +40 mV by electrical stimulation of PB inputs. Noradrenaline reduced the NMDA receptor-mediated EPSC to a similar extent as the AMPA receptor-mediated EPSC recorded at À60 mV (72.1% ± 8.2% inhibition measured 50 ms poststimulation, p < 0.05, n = 4, Figure 5A ). This result is consistent with a presynaptic action of noradrenaline, as it is unlikely that postsynaptic modulation by noradrenaline would affect both receptor types equally.
We next investigated whether noradrenaline reduces synaptic efficacy by modulating transmitter release probability. To monitor release probability, we measured the ratio of the postsynaptic response to two stimuli delivered at an interval of 50 ms, the paired-pulse ratio (PPR) (Zucker, 1989) . Application of noradrenaline resulted in a similar block in the amplitude of both EPSCs with no significant change in PPR ( Figure 5B ; 1.35 ± 0.05 in control and 1.41 ± 0.08 in noradrenaline, n = 26, p = 0.27). In contrast, lowering extracellular calcium to 0.5 mM ( Figure 5C ) or activating presynaptic GABA B receptors using the selective agonist baclofen (2 mM; Figure 5D ), manipulations that reduce release probability, both reduced PB-CeAL EPSCs to a similar degree as that achieved by 10 mM noradrenaline (58.2% ± 5.2% and 57.3% ± 4.9%, respectively) but were also accompanied by clear increases in PPR ( Figure 5E ; from 1.35 ± 0.09 to 1.68 ± 0.07 for low calcium and 1.30 ± 0.06 to 1.63 ± 0.12 for baclofen, n = 12 and 10, p < 0.01). Together with the reduction in frequency of asynchronous events evoked in strontium ( Figure 4B ), these results show that noradrenaline reduces transmitter release at PB inputs by a presynaptic mechanism that does not change release probability.
Noradrenaline Reduces the Number of Presynaptic Release Sites
At synapses with a number of release sites (N) with an average release probability p, the response of the postsynaptic neuron is given by N 3 p 3 q, where q is the response to release of a quantum of transmitter at one release site (Katz and Miledi, 1972) . We have shown that reduction of the EPSC at PB inputs is not due to a change in the amplitude of miniature EPSCs (q) or the release probability (p). To test whether noradrenaline could change N, we used variance mean analysis (Clements, 2003 ) (see Experimental Procedures). Variance-mean curves for PB-CeAL EPSCs stimulated in control conditions and in the presence of 10 mM noradrenaline were generated for a range of release probabilities by altering the calcium:magnesium ratios in the perfusing solution ( Figure 6 ). The average variance and mean across cells for each external calcium/magnesium concentration in control or in noradrenaline (n = 8) were fitted with parabolic functions (see Experimental Procedures). On visual inspection, the shape of these curves is consistent with noradrenaline producing a change in the number of release sites with no change in release probability (Clements, 2003; Foster and Regehr, 2004) . This analysis indicates that the lower limit to the number of release sites (N T ) was 17 in the control condition, whereas application of noradrenaline reduced it to 7 (a 59% reduction in release sites). The derived quantal current amplitude (q) in control and noradrenaline were similar (12.1 pA and 11.8 pA, 884 Neuron 56, 880-892, December 6, 2007 ª2007 Elsevier Inc.
Neuron
Noradrenergic Inhibition in the Central Amygdala respectively) and close to the amplitude of quantal events evoked in strontium ( Figure 4B ; mEPSC amplitude 13.6 pA, n = 6 cells). Moreover, at 2.5 mM Ca 2+ , the estimated release probability was 0.46 under control conditions and 0.48 in 10 mM noradrenaline. These results show that noradrenaline acts to reduce the number of release sites without affecting the quantal size or release probability.
Noradrenergic Modulation Is Independent of Presynaptic Calcium Influx
We have shown that noradrenaline acting at a2 adrenoceptors reduced transmitter release at parabrachial inputs by a mechanism that did not involve a reduction in release probability. Instead, variance-mean analysis suggests that noradrenaline reduces the number of active release sites. a2 adrenoceptors are thought to be coupled to pertussis toxin-sensitive Gi/o type G proteins (Hein, 2006 ), and we next tested the downstream effector mechanisms activated. Uncoupling petussis toxin-sensitive G proteins with either pertussis toxin (4 hr incubation at 34 C in 5 mg/ml) or the sulphydryl alkylating agent N-ethylmaleimide (NEM, bath applied for 15 min at 250 mM) (Hoshino et al., 1990) blocked noradrenergic inhibition ( Figure 7A ; NEM, 6.4% ± 3.2% inhibition; PTX, 9.6% ± 16.1% inhibition; p > 0.05, n = 4 and 3, respectively), indicating that Gi/o activation was required. To confirm that the effects of noradrenaline were mediated by presynaptic receptor activation, we replaced the GTP in our internal solution with its nonhydrolysable analog (GTPgS; 0.3 mM). As expected, in neurons postsynaptically loaded with GTPgS, the postsynaptic effects of the GABA B agonist baclofen were fully blocked (n = 4, data not shown); however, PB-CeAL EPSCs remained sensitive to noradrenaline ( Figure 7A ; 61.5% ± 7.4% inhibition, p < 0.05, n = 4), consistent with a presynaptic action of noradrenaline. To test whether the actions of noradrenaline were mediated by Gbg subunits, we next applied the membrane-permeant Gbg-binding peptide mSIRK (Chen et al., 2005) . We found that direct application of mSIRK to the presynaptic terminals by low-pressure application (20 mM, 10-15 min) blocked the effect of noradrenaline ( Figure 7A ; pre/post mSIRK, 2.9% ± 11.9% inhibition; n = 5, p = 0.4). In contrast, loading mSIRK into the postsynaptic neuron had no effect ( Figure 7A ; EPSC amplitude post mSIRK, 72.5 ± 5.6 inhibition, p < 0.01, n = 4). Thus, noradrenergic modulation of transmitter release at these PB-CeAL synapses requires activation of presynaptic Gi/o proteins and is mediated by Gbg signaling.
Inhibition of transmitter release by activation of presynaptic G protein-coupled receptors has been demonstrated for many neurotransmitters (including noradrenaline), where the presynaptic actions of these receptors are mediated by released Gbg subunits that act either on voltage-dependent calcium channels or potassium channels, both of which effectively reduce calcium influx and reduce transmitter release (Chieng and Bekkers, 1999; Miller, 1998) . This inhibition is selective for particular subtypes of calcium channel (Chieng and Bekkers, 1999; Dolezal et al., 1996) . Thus, while we do not see a change in release probability, it is conceivable that a site-specific inhibition of these multi-release-site terminals by noradrenaline is due to differential expression of VGCCs and a2-adrenoceptors at individual release sites. If this were the case, then the inhibition of calcium influx at a subset of sites containing both the a2-adrenoceptor and the appropriate VGCC would reduce release from these sites only. To test whether presynaptic calcium influx is reduced by noradrenaline, we loaded PB basket terminals with the low-affinity fluorescent calcium indicator magnesium green (Figure 2 ). Application of noradrenaline had no effect on action potential-driven calcium influx into the PB terminals (10 mM, Figure 7B ). In contrast, calcium influx was significantly reduced by the GABA B agonist baclofen (1 mM, Figure 7B ) (Isaacson, 1998) and completely blocked by the VGCC blocker cadmium (50 mM, Figure 7B ). These experiments demonstrate that there is no change in the action potential-driven rise in terminal free calcium across the entire terminal, showing that noradrenaline acts downstream of calcium influx. How then does noradrenaline reduce transmitter release?
G protein receptor-mediated effects on transmitter release downstream of calcium influx have also been previously proposed (Blackmer et al., 2001; Chen et al., 2005; Dittman and Regehr, 1996; Miller, 1998; Nicola and Malenka, 1997; Scanziani et al., 1992) . Moreover, recent studies have found that at lamprey giant reticuospinal terminals these actions are mediated by Gbg subunits that inhibit vesicular release Gerachshenko et al., 2005) by binding to the C terminus of SNAP-25 , a key component of the SNARE complex (Gerachshenko et al., 2005) . To test whether noradrenergic modulation at PB-CeAL synapses was similarly mediated by Gbg interaction with the release machinery, we incubated slices in botulinum toxin A (BoNT A, 0.2 nM), which cleaves the Gbg binding site on the SNAP-25 , and tested the effect of noradrenaline. Incubation of slices in BoNT reduced the amplitude of the evoked EPSC ( Figure 7C ) and, consistent with previous studies (Gerachshenko et al., 2005) , noradrenergic inhibition was reduced with increasing incubation time in BoNT ( Figure 7C) , showing that the reduced availability of functional Gbg interaction sites on SNAP-25 reduces the effect of noradrenaline at PB-CeAL synapses.
As noradrenergic modulation appears to interact with the vesicular release machinery directly, it is possible that activation of a2 receptors could also affect docking of new vesicles to presynaptic active zones. If vesicles were prevented from docking, then presumably those release sites would become silent through activity-driven depletion of releasable vesicles (a process that might have occurred as we stimulated at regular intervals while we allowed noradrenaline to perfuse onto our slice preparation). To test this possibility, we applied noradrenaline in the absence of stimulation of the PB input. We found that the evoked PB EPSC was immediately blocked to maximal extent when stimulation recommenced in noradrenaline ( Figure 7D ), indicating that activity-driven depletion was not required for the action of noradrenaline and suggesting that the release machinery itself is the likely target of noradrenergic block.
We have shown that noradrenaline reduces transmitter release at parabrachial terminals in the CeAL by a presynaptic mechanism that does not change release probability. In contrast, activation of GABA B receptors with baclofen, which also reduces transmitter release, was accompanied by a reduction in release probability. What then is the functional significance of these two different types of presynaptic modulation? Transmitter release is gated by a rise in presynaptic calcium and follows a power relationship so that small changes in calcium are translated into significantly larger changes in transmitter release (Dodge and Rahamimoff, 1967) . As noradrenaline reduces transmitter release without changing release probability, we predicted that conditions that increase release probability (such as a build up of residual calcium during trains of action potentials) would be less effective in relieving inhibition than for inhibitors that lower release probability, such as baclofen. Two results support this idea. First, paired-pulse stimulation shows that the amplitude of the second EPSC is greatly enhanced relative to the first in the presence of baclofen as compared to noradrenaline. Thus, while both baclofen and noradrenaline reduced the EPSC by a similar extent, facilitation of the second EPSC was 63% in baclofen as compared to 41% in noradrenaline ( Figure 5) . Similarly, raising extracellular calcium from 2.5 mM to 4.5 mM in the presence of noradrenaline (10 mM, Figure 7E , top) increased evoked EPSC amplitude and reduced PPR similarly to that seen when raising calcium in the same manner in control conditions (amplitude: 21.5% ± 9.3% increase in NAd, n = 8, p < 0.05 compared to 28.1% ± 8.3% in control. PPR: 8.1% ± 1.1% in noradrenaline compared with 9.0% ± 3.1% in control, n = 9 and 8, respectively, ANOVA p > 0.05). In contrast, increasing external calcium in the presence of baclofen (2 mM, Figure 7E , bottom) produced a significant increase in amplitude (42.2% ± 2.7%, n = 4, p < 0.05) and a larger reduction in PPR than in control or noradrenaline (26.0% ± 3.1%, n = 4, ANOVA p < 0.05 for both conditions).
Synaptic Release of Noradrenaline Inhibits PB Input
The CeAL receives significant noradrenergic innervation from the nucleus tractus solitarius and the locus coeruleus (Fallon et al., 1978) . To identify the sites of terminations of these afferents, sections where the PB terminals were labeled with DiI were immunostained for the enzyme dopamine-b-hydroxylase (DBH). These DBH-positive fibers were found in close apposition with the perisomatic PB terminals ( Figure 8A ). Histochemical and fiber tracing studies have shown that noradrenergic fibers enter the central amygdala via the ventral amygdalofugal pathway (VAF) and the bed nucleus of the stria terminalis (Fallon et al., 1978) , which is also the pathway for the excitatory PB input to the CeA ( Figure 1C ), and where we had positioned our bipolar stimulating electrode to elicit PBEPSCs. Thus, it seems likely that our stimulation paradigm would also activate noradrenergic afferents into the CeAL. However, application of the a 2 -specific antagonist yohimbine had no significant effect on the evoked PB-CeAL EPSC ( Figure 3D ; 8.8% ± 4.4% decrease, n = 7, p = 0.7), indicating that little or no noradrenaline is released under our baseline stimulation (up to 0.17 Hz) and recording conditions. To increase noradrenaline release, afferent fibers were stimulated with short high-frequency trains (5 stimuli at 50 or 100 Hz). The brief tetanus was followed with a test stimulus that was compared to a single isolated stimulus with no preceding train ( Figure 8B ). We found that the EPSC evoked 100 ms after the train of stimuli was inhibited by 23.8% ± 2.5% (Figures 8C and 8D ; p < 0.01, n = 18), an effect fully blocked by the a 2 -adrenoceptor antagonist yohimbine ( Figure 8C ; 1.2% ± 1.8% inhibition, p = 0.49, n = 9). This inhibition was significantly potentiated by the subsequent application of the selective noradrenaline uptake inhibitor reboxetine ( Figure 8C , 10 mM) to 30.3% ± 3.1% (p < 0.01, n = 9). This action of noradrenaline had a prolonged time course of action, lasting up to 1 s, and was potentiated throughout its time course by reboxetine, consistent with its actions on noradrenaline uptake. At 1 s after the brief tetanus, noradrenergic inhibition was 4.5% ± 2.0% (p < 0.05, n = 5) under control conditions, but was greatly enhanced when uptake was subsequently blocked with reboxetine, increasing to 18.9% ± 4.3% ( Figure 8E ; p < 0.05, n = 4).
DISCUSSION
In this study we have shown that neurons in the lateral sector of the central amygdala receive a potent excitatory input from the parabrachial nucleus that carries ascending nociceptive information. Single parabrachial fibers form large perisomatic synapses that have multiple release sites and can drive postsynaptic cells to threshold. This region is also extensively innervated by noradrenergic afferents (Fallon et al., 1978) , and we show that noradrenaline released by these afferents selectively activates presynaptic a2 adrenoceptors on parabrachial inputs, leading to inhibition of transmitter release. This inhibition requires Gbg subunits that act to reduce the number of active release sites.
Inhibition of transmitter release by presynaptic autoreceptor activation has been recognized for many years. At mammalian synapses, a range of transmitters acting at either metabotropic (Miller, 1998) or ionotropic (MacDermott et al., 1999) receptors can inhibit transmitter release. Three general mechanisms have been described to explain these presynaptic actions (Miller, 1998; Wu and Saggau, 1997) . These are (1) inhibition of presynaptic calcium channels that are responsible for initiating transmitter release; (2) activation of presynaptic ion channels, typically potassium or chloride channels that effectively shunt the presynaptic terminal and either reduce calcium influx or block action potential invasion, and (3) regulation of the vesicle release complex downstream of calcium influx. Of these, the first two mechanisms both result in a reduction of terminal calcium (Dittman and Regehr, 1996; Wu and Saggau, 1994 ) and a consequent reduction of transmitter release by reducing transmitter release probability (Delaney and Jahr, 2002; Manabe et al., 1993) . At mammalian synapses, the third mechanism has generally been inferred as a result of changes in the frequency of spontaneous transmitter release, a process that is independent of calcium (Thompson et al., 1993) . Moreover, in cases where such a mechanism has been suggested, the presynaptic modulator involved (adenosine, GABA) additionally has actions on presynaptic calcium (Dittman and Regehr, 1996) and consequent changes in release probability. Indeed, it has been suggested that while modulation of the release complex may play a role, presynaptic inhibition is largely achieved by changes in calcium influx (Dittman and Regehr, 1996; Miller, 1998; Wu and Saggau, 1997) . We show here that noradrenergic modulation of the PB inputs to CeAL neurons is entirely due to an effect on the release complex, with no effect on calcium influx or release probability.
Adrenergic a2 receptors are G protein-coupled receptors (Hein, 2006) . Recent studies have shown that Gbg can inhibit vesicular release downstream of calcium entry (Blackmer et al., 2001) , possibly by directly binding to SNAP25 Chen et al., 2005; Gerachshenko et al., 2005) . Consistent with these findings, we show that scavenging Gbg subunits with mSIRK blocks noradrenergic inhibition at these synapses and that reducing the available SNAP-25 Gbg-binding sites also reduced the effect of noradrenaline. Notably, noradrenergic inhibition of transmitter release was never complete (Figure 3) . Differential expression of noradrenergic receptors or the composition of the SNARE complex at individual release sites on the basket terminal could lead to inhibition of release from this subset of sites, resulting in a change in the number of sites contributing to action potentialdriven release, i.e., a change in N. Functionally, such a mechanism results in presynaptic inhibition that would be less susceptible to relief by residual calcium building up in the terminals during repetitive presynaptic activity. Presynaptic inhibition that reduces release by downregulating calcium influx, such as GABA B -mediated presynaptic inhibition (Isaacson, 1998) , may result in fewer sites releasing early in a train of action potentials, but as residual calcium builds up within the terminals during the train, all of the release sites could potentially participate in the action potential-evoked response. In contrast, a mechanism of presynaptic inhibition that reduces the number (C) Overlaid test responses (indicating the EPSC was preceded by a short high-frequency train) in control, in the presence of the selective noradrenaline reuptake inhibitor reboxetine (10 mM), and in reboxetine and yohimbine 10 and 20 mM, respectively). (D) Summary data showing the inhibition of the test response stimulated 100 ms after the brief high-frequency train, in control conditions (p < 0.01, n = 18), in 10 mM reboxetine (p < 0.01, n = 11), and in 20 mM yohimbine (p = 0.49, n = 9). (E) Time course for the inhibition of test EPSCs following a short high-frequency stimulus train (5 stimuli at 100 Hz) in control (filled circles) and following application of reboxetine (unfilled squares). Significance levels are indicated by stars: *p < 0.05, **p < 0.01. n = 5-10 for each time point.
of release sites available still limits the number of sites that might participate in transmission regardless of the build up of residual calcium and increase in release probability.
Synaptically released noradrenaline caused a clear reduction in transmitter release by activating a2 adrenoreceptors. Neurons in the CeAL also express postsynaptic calcium-dependent potassium channels that mediate the slow AHP (Lopez de Armentia and Sah, 2004) . As with many other neurons (Sah, 1996) , this slow AHP is modulated by b adrenoceptors (Lopez de Armentia and Sah, 2004) . Interestingly, synaptically released noradrenaline, despite having clear effects on presynaptic adrenoceptors, had no effect on the slow AHP in these neurons, even when noradrenaline uptake was blocked with reboxetine (A.J.D. and P.S., unpublished data). The reasons for such an organization are not clear, but these observations do suggest that synaptically released noradrenaline has little or no access to postsynaptic b adrenoceptors in CeAL neurons.
Pain is a conscious experience in which nociceptive inputs are integrated with cognitive and emotional factors. The amygdala plays a key role in assigning affective valence to sensory stimuli (Davis and Whalen, 2001; LeDoux, 2000) , and the spino-parabrachio-amygdaloid nociceptive pathway is involved in integrating the autonomic and emotional aspects of pain (Bernard et al., 1996; Neugebauer et al., 2004) . Neurons in the lateral division are innervated by large perisomatic basket terminals from neurons in the pain-responsive PB (Sarhan et al., 2005) . The highly specialized anatomy of these terminals provides large suprathreshold excitatory inputs and thus is particularly well suited to providing a reliable source of ascending nociceptive information to the CeA. Activation of stress/ arousal circuits are well known to lead to increased noradrenaline release in the CeA (Morilak et al., 2005) , a structure that is involved in the generation of stress-induced analgesia seen in both animals and humans (Bellgowan and Helmstetter, 1996; Rhudy and Meagher, 2000) . Our results suggest that an important mediator of stressinduced analgesia could be the potent modulation by noradrenaline of nociceptive PB inputs in the central amygdala.
EXPERIMENTAL PROCEDURES Brain Slices
Slices were prepared from 21-to 42-day-old Wistar rats (including DiI-labeled rats) in accordance within the guidelines of the Institutional Animal Ethics Committee. Rats were anesthetized using halothane, decapitated, and their brains removed into ice-cold ACSF solution containing (in mM) 118 NaCl, 25 NaHCO 3 , 10 glucose, 2.5 CaCl 2 , 1.2 NaH 2 PO 4 , and 1.3 MgCl 2 . Brains were sliced into 350 mm thick coronal sections using a Leica VT1000S vibratome at 0 C, transferred to a chamber containing ACSF at 33 C-34 C for 30 min, and then maintained for several hours in ACSF at room temperature. Whole-cell recordings were made from brain slices maintained at 32 C-33 C in a recording chamber continuously perfused with oxygenated ACSF and visualized using IR/DIC techniques. Recording electrodes (3-5 MU) were filled with pipette solution containing (mM) CsMeSO 4 135, NaCl 8, HEPES 10, Mg 2 ATP 2, and Na 3 GTP 0.3 (pH 7.2 with CsOH, osmolarity 290 mOsm/kg). Whole-cell voltageclamp recordings were made using a patch-clamp amplifier (Multiclamp 700A, Axon Instruments, Foster City, CA) controlled by an Apple Macintosh G4 computer. Current signals were filtered at 4-8 kHz and digitized at 20 kHz (Instrutech ITC18, Greatneck, NY), acquired, stored, and analyzed on the Macintosh G4 using Axograph software (Axon Instruments). Access resistance was 5-20 MU and was monitored throughout the experiment. GABAergic transmission was blocked with picrotoxin (100 mM) and CGP53855A (1 mM) in the external solution.
EPSCs were evoked using either a theta glass stimulator placed into the slice or a concentric bipolar stimulator placed just over the surface of the slice. Responses shown are averages of 10-50 individual trials. Student's t tests were used for statistical comparisons between groups (except where indicated as otherwise). Results are expressed as mean ± SEM. Drugs were added to the superfusate, including (Sigma) picrotoxin and reboxetine and NEM, (Tocris) CGP55845A, noradrenaline, clonidine, cirazoline, yohimbine, prazosin, isoprenaline, and NBQX (from calbiochem), mSIRK, and (Alamone) TTX. Slices were incubated in Pertussis toxin (Sigma-Aldrich) and botulinum toxin A (gift from Dr Meunier) at 32 C.
DiI Labeling
Male Wistar rats (4-5 weeks of age) were anesthetized with a ketamine (100 mg/kg)/xylazine (20 mg/kg) mixture. After animals were placed in a stereotaxic frame, an incision was made to expose the skull surface. A small hole was drilled in the skull, and the underlying dura was removed. A micropipette filled with DiI (Molecular Probes, Eugene, OR) was lowered into the left parabrachial nucleus (9.0 mm caudal to bregma; 2.4 mm lateral to midline; 7.3 mm ventral to skull surface). After positive pressure was applied to the pipette to deliver 50-100 nl of DiI, the pipette was left in place for 5 min to minimize diffusion of the DiI back along the injection tract. The pipette was then removed, the hole sealed with bone wax, and the incision closed with surgical staples. After 7 days for transport of DiI, animals were either used for electrophysiological recordings as described above, or they were anesthetized with sodium pentobarbitone (80 mg/kg, i.p.) and perfused transcardially with 2% sodium nitrite solution (in 0.1 M phosphate buffer, pH 7.4) followed by 500 ml of 4% formaldehyde (in 0.1 M phosphate buffer, pH 7.4). Brains were then removed, postfixed for 2 hr, and cryoprotected overnight in 10% sucrose (in 0.1 M phosphate-buffered saline [PBS], pH 7.4) at 4 C. Serial, coronal forebrain (40 mm), and brainstem (50 mm) sections were cut using a freezing microtome.
Immunolabeling
Forebrain sections containing the amygdala were washed in PBS, blocked for 1 hr in 3% BSA, and incubated overnight in mouse antidopamine-b-hydroxylase (1:1000; Chemicon International, USA). Sections were then washed in PBS before a 2 hr incubation in goat anti-mouse-Alexa Fluor-488 (1:300, Molecular Probes, Eugene, OR). Following another PBS wash, all sections were mounted onto subbed slides and coverslipped with fluorescent mounting medium (DakoCytomation, Denmark). A series of sections through the parabrachial nucleus were also mounted and coverslipped to allow the placement of the injection site to be determined. IR-DIC and low-resolution DiI fluorescence images were captured from analog video images from a Dage MTi IR1000Ex camera attached to an Olympus BX51WI microscope, using a Lifeview CAPVIEW USB video capture device. High-resolution images were captured on either a Zeiss Axioplan-2 fluorescence microscope using Axiovision 3.1 imaging software or on a Zeiss LSM 510 Meta confocal microscope.
Variance Mean Analysis
Given a synaptic connection with N release sites, with an average release probability of p, the response to stimulation is given by Npq, where q is the response to a single quantum of transmitter, then the variance in the amplitude of the evoked synaptic current is given by s 2 = Nq 2 pð1 À pÞ:
When the synapse is stimulated repeatedly, the mean synaptic current I is given by I = Npq. Under these conditions, the variance of the synaptic current s 2 is related to the mean current by (Clements, 2003; Silver, 2003) 
For synapses with multiple release sites, as in the case of the parabrachial inputs to CeAL neurons, variability in quantal size between release sites (intersite variability) and variability at each site (intrasite variability), determined by factors such as vesicle filling and latency of release, need to be included (Foster and Regehr, 2004) . Total variance is related to the mean current by
where CV QII is the intersite variability and CV QI is the intrasite variability.
For somatic PB synapses, we determined the total quantal variability (CV adrenaline. The variance of these responses was plotted against the mean response amplitude at each calcium/magnesium concentration to construct individual variance mean plots, and the average variance and mean for each calcium/magnesium ratio across cells was used to construct the population variance mean plot. The population variance mean plot was fit with a parabolic function (Equation 3) to estimate the parameters q and N.
Calcium Indicator Loading
Membrane-permeant calcium indicators (Magnesium Green-AM and Oregon Green 488 BAPTA-1 AM, 50 ng; Molecular Probes, Eugene, OR) were dissolved in 5 ml pluronic acid/DMSO and 45 ml dry DMSO with vortexing, then diluted to a final concentration with 50 ml filtered ACSF and sonicated for 15 min. Indicator was applied under low pressure via a low-resistance patch pipette into the ventral-amygdalofugal fiber bundle in a 350 mm thick coronal slice maintained at 32 C in a perfusion chamber oriented to provide solution flow away from the CeAL ( Figure 7A ). Loaded slices were incubated for 2-3 hr before calcium imaging.
Parabrachial Fiber Stimulation and Terminal Calcium Imaging
Parabrachial fibers were stimulated electrically using a bipolar stimulating electrode placed adjacent to the labeling site. Whole-field fluorescence measurements were recorded using a monochromatorbased imaging system (Polychrome V; T.I.L.L. Photonics, Martinsried, Germany). Labeled PB terminals were illuminated with 488 nm light and visualized using a 403 water-immersion objective. Images were acquired with an in-line transfer, cooled CCD camera (T.I.L.L. Photonics). Images were analyzed off-line using Vision (T.I.L.L Photonics). Kinetic sequences were then constructed over time for each of the selected labeled terminals. Calcium signals were measured as the relative change in fluorescence over baseline fluorescence (DF/F).
